Safety evaluation and toxicology studies and related services for drug development
Active Awarded
- Contract number
- 75N95024D00021
- Awardee
-
Lovelace Biomedical Research Institute UEI MBT9RXJJ7428
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Task orders
- 0
Award facts
- Opportunity
-
- Safety Evaluation and Toxicology Studies and Related Services for Drug Development Pre-Solicitation · 75N95023R00029 · Posted May 11, 2023
- Last date to order 39% complete
- IDV ceiling
- $48,622,546.00
- Maximum order
- $48,622,546.00
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 6 offers Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
This indefinite delivery contract (IDC) was awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to Lovelace Biomedical Research Institute, a not-for-profit contract research organization. The $48.6 million multiple-award IDC has a 6-year ordering period from June 2024 to June 2030.
The contract aims to procure safety evaluation and toxicology studies and related services to support drug development efforts at NCATS. This includes in vitro and in vivo exploratory and IND-directed toxicology studies for small molecule and biological drug candidates. The work spans areas such as genetic toxicology, general toxicology, safety pharmacology, and reproductive/carcinogenesis studies, with data to be prepared in a format suitable for regulatory submissions. Lovelace will perform this work on a task order basis, leveraging its expertise in areas like animal model development and preclinical testing across therapeutic modalities. The contract was competed on a full and open basis without any small business set-asides.
Quick answers
Who was awarded contract 75N95024D00021?
75N95024D00021 was awarded to Lovelace Biomedical Research Institute by National Institute on Drug Abuse (National Institutes of Health) on June 20, 2024.
How much is contract 75N95024D00021 worth?
75N95024D00021's own ceiling is $48,622,546. A single order can be worth up to $48,622,546.
Which agency awarded contract 75N95024D00021?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95024D00021, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Who can order from contract 75N95024D00021?
75N95024D00021 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Is contract 75N95024D00021 part of a contract vehicle?
Yes. 75N95024D00021 is part of Safety Evaluation and Toxicology Studies and Related Services for Drug Development.
Was contract 75N95024D00021 competed?
The extent of competition for 75N95024D00021 was full and open competition. The government received 6 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV